A method of monitoring disease progression of a patient receiving treatment with a therapeutic agent that binds to and modulates IFNα activity comprising: obtaining a first IFNα-inducible PD marker expression profile in a first sample from the patient； administering a therapeutic agent that binds to and modulates IFNα activity； obtaining a second IFNα-inducible PD marker expression profile in a second sample from the patient； and comparing the first and the second IFNα-inducible PD marker expression profiles, wherein a variance in the first and the second IFNα-inducible PD marker expression profiles indicates a level of efficacy of the therapeutic agent that binds to and modulates IFNα activity.
